Millipore Sigma Vibrant Logo

NA14 Anti-Topoisomerase II (Ab-1) Mouse mAb (SWT3D1)

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.
View Products on Sigmaaldrich.com
NA14
  
Prix en cours de récupération
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
Maximum Quantity is
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
—
Demander le prix
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

       

      Contacter le Service Clients

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      Species ReactivityHostAntibody Type
      HMMonoclonal Antibody
      Description
      Overview

      This product has been discontinued.



      Recognizes ~170 kDa topoisomerase II protein in HeLa cells and breast carcinoma tissue.
      Catalogue NumberNA14
      Brand Family Calbiochem®
      References
      Referencesvan der Zee, A.G., et al. 1994. Ann. Oncol. 5, 75.
      Cummings, J. and Smyth, J.F. 1993. Ann. Oncol. 4, 533.
      Robinson, R.G., et al. 1993. Hybridoma 12, 407.
      Anderson, H.J. and Roberge, M. 1992. Cell Biol. Intl. Reports 16, 717.
      Gasser, S.M., et al. 1992. J. Antonie Van Leeuwenhoek 62, 15.
      Tan, K.B., et al. 1992. Can. Res. 52, 231.
      Osheroff, N., et al. 1991. Bioessays 13, 269.
      Chung, T.D.Y., et al. 1989. Proc. Natl. Acad. Sci. USA 86, 9431.
      Wang, J.C. 1985. Ann. Rev. Biochem. 54, 665.
      Product Information
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 2% gelatin.
      Negative controlP388D cells
      Positive controlHeLa cells or breast carcinoma tissue
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Application ReferencesImmunoblotting Robinson, R.G., et al. 1993. Hybridoma 12, 407.
      Key Applications Immunoblotting (Western Blotting)
      Not Immunoprecipitation
      Paraffin Sections
      Application NotesImmunoblotting (5 µg/ml, see application references)
      Paraffin Sections (2.5 µg/ml, pressure cooker pre-treatment required)
      Immunoprecipitation (not recommended)
      Application CommentsHas a high affinity for topoisomerase IIα and a low to moderate affinity to topoisomerase IIβ. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenrecombinant human topoisomerase IIα
      ImmunogenHuman
      CloneSWT3D1
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Yes
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      NA14 0

      Documentation

      Anti-Topoisomerase II (Ab-1) Mouse mAb (SWT3D1) FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Anti-Topoisomerase II (Ab-1) Mouse mAb (SWT3D1) Certificats d'analyse

      TitreNuméro de lot
      NA14

      Références bibliographiques

      Aperçu de la référence bibliographique
      van der Zee, A.G., et al. 1994. Ann. Oncol. 5, 75.
      Cummings, J. and Smyth, J.F. 1993. Ann. Oncol. 4, 533.
      Robinson, R.G., et al. 1993. Hybridoma 12, 407.
      Anderson, H.J. and Roberge, M. 1992. Cell Biol. Intl. Reports 16, 717.
      Gasser, S.M., et al. 1992. J. Antonie Van Leeuwenhoek 62, 15.
      Tan, K.B., et al. 1992. Can. Res. 52, 231.
      Osheroff, N., et al. 1991. Bioessays 13, 269.
      Chung, T.D.Y., et al. 1989. Proc. Natl. Acad. Sci. USA 86, 9431.
      Wang, J.C. 1985. Ann. Rev. Biochem. 54, 665.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-September-2007 RFH
      ApplicationImmunoblotting (5 µg/ml, see application references)
      Paraffin Sections (2.5 µg/ml, pressure cooker pre-treatment required)
      Immunoprecipitation (not recommended)
      DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with P3X63Ag8.653 mouse myeloma cells. Recognizes the ~170 kDa topoisomerase II protein.
      BackgroundTopoisomerase II is a nuclear enzyme whose primary function is to induce temporary double-strand breaks in DNA and to facilitate the passage of the duplex DNA segments through these breaks. Phosphorylation of topoisomerase II in a cell cycle regulated manner appears to be important for progression through the cell cycle. The enzyme exists as two discrete isozymes, topoisomerase IIα (~170 kDa) and topoisomerase IIβ (~180 kDa) which are under independent transcriptional regulation. Both isozymes have been identified in human and mouse cells but only the topoisomerase IIα form appears in yeast. The gene encoding topoisomerase IIα has been mapped to chromosome 17 and is in close proximity to the gene for erbB-2. Altered expression of topoisomerase II has been documented in many cancers including AML, CLL, small cell lung cancer, breast and ovarian cancer, and colon cancer. Based on this observation, topoisomerase II has been identified as the target of many widely used antineoplastic drugs as well as the target of rational drug design.
      HostMouse
      Immunogen speciesHuman
      Immunogenrecombinant human topoisomerase IIα
      CloneSWT3D1
      IsotypeIgG₁
      Specieshuman, not mouse, not rat
      Positive controlHeLa cells or breast carcinoma tissue
      Negative controlP388D cells
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 2% gelatin.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsHas a high affinity for topoisomerase IIα and a low to moderate affinity to topoisomerase IIβ. Antibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Yes
      Toxicity Standard Handling
      Referencesvan der Zee, A.G., et al. 1994. Ann. Oncol. 5, 75.
      Cummings, J. and Smyth, J.F. 1993. Ann. Oncol. 4, 533.
      Robinson, R.G., et al. 1993. Hybridoma 12, 407.
      Anderson, H.J. and Roberge, M. 1992. Cell Biol. Intl. Reports 16, 717.
      Gasser, S.M., et al. 1992. J. Antonie Van Leeuwenhoek 62, 15.
      Tan, K.B., et al. 1992. Can. Res. 52, 231.
      Osheroff, N., et al. 1991. Bioessays 13, 269.
      Chung, T.D.Y., et al. 1989. Proc. Natl. Acad. Sci. USA 86, 9431.
      Wang, J.C. 1985. Ann. Rev. Biochem. 54, 665.
      Application referencesImmunoblotting Robinson, R.G., et al. 1993. Hybridoma 12, 407.